86 Chapter 4 (0.85; 95% CI = −0.15 to 1.85; p = 0.112) but MAMD was increased in the first month after infection with 1.11 days (95% CI = 0.10–1.62; p = 0.027). Crude means without statistical modelling are visualized in Figure 1, adjusted estimates per outcome measure are shown in Table 2. Subgroup analysis showed an increase in days with analgetic intake in the first month after infection compared to baseline (1.18; 95% CI = 0.43–1.92; p = 0.002). However, this effect was not seen for medication days with triptan intake (–0.05; 95% CI = –0.53 to 0.43; p = 0.846). In addition, the increase in analgesic intake days was observed predominantly when combining non-migrainous headache days with non-headache days (0.79; 95% CI = 0.23–1.35; p = 0.006), but was not found for non-headache days alone (0.33; 95% CI = –0.07 to 0.72; p = 0.104). Figure 1: Crude means ± SEM for migraine-related outcomes during baseline and first two months following infection. *p ≤ 0.05 in linear mixed model.
RkJQdWJsaXNoZXIy MjY0ODMw